This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kopp, R. Articles by Pfeiffer, A. Search for Related Content PubMed PubMed Citation Articles by Kopp, R. Articles by Pfeiffer, A.

Suramin Alters Phosphoinositide Synthesis and Inhibits Growth Factor Receptor Binding in HT-29 Cells¹

Departments of Surgery and Internal Medicine II, Klinikum Grosshadern, University of Munich, West Germany

Initiation of cell growth frequently involves activation of growth factor receptor-coupled tyrosine kinases and stimulation of the phosphoinositide second messenger system. The antitrypanosomal and antifiliarial drug suramin has been shown to exert antiproliferative activities by inhibition of growth factor receptor binding. We therefore investigated the effect of suramin on epidermal growth factor receptor-binding characteristics and, additionally, searched for effects on basal or cholinergically stimulated phospholipid metabolism in HT-29 cells.

Suramin caused a dose-dependent and noncompetitive inhibition of ¹²⁵I-epidermal growth factor binding (concentration producing 50% inhibition, 44.2 µg/ml) but did not alter muscarinic receptor binding. Suramin did not affect the basal ³²P incorporation into phosphoinositides at concentrations of <200 µg/ml suramin. In contrast, the carbachol-stimulated enhancement of ³²P incorporation into phosphatidic acid, phosphatidylinositol, and polyphosphoinositides was reduced by 48–95% in the presence of 100 µg/ml suramin. Thus, phosphoinositide and diacylglycerol kinases involved in basal and receptor-stimulated phosphoinositide metabolism may be localized in different subcellular compartments, which can be dissociated by the use of suramin. Direct measurements of phosphatidylinositol kinase and diacylglycerol kinase activities showed a potent inhibition when treated with suramin. Suramin did not affect the stimulation of phospholipase C by carbachol, determined by release of [³H]inositol phosphates in [³H]myoinositol-prelabeled cells.

Our data indicate that suramin potently inhibits phosphoinositide resynthesis under stimulated conditions. Additionally, we confirm the inhibitory effects of suramin on epidermal growth factor receptor binding in a human intestinal cell line. The inhibitory effects of suramin on phospholipid metabolism may play a role in the antiproliferative actions of this drug.

¹ This work was supported by the Wilhelm Sander-Stiftung (grant 86.018.1). Part of this study was presented at the Annual Meeting of the American Gastroenterological Society, Washington, DC, May 1989 (Gastroenterology, 1989, abstract).

² To whom requests for reprints should be addressed, at Chirurgische Klinik, Klinikum Grosshadern, Folab B VE01-320, Universität München, Marchioninistr. 15, 8000 München 70, West Germany.

Received 12/13/89. Accepted 7/ 2/90.

This article has been cited by other articles:

				M. A. Villalona-Calero, G. A. Otterson, M. G. Wientjes, F. Weber, T. Bekaii-Saab, D. Young, A. J. Murgo, R. Jensen, T.-K. Yeh, Y. Wei, et al. Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study Ann. Onc., November 1, 2008; 19(11): 1903 - 1909. [Abstract] [Full Text] [PDF]

				C. Werth, D. Stuhlmann, B. Cat, H. Steinbrenner, L. Alili, H. Sies, and P. Brenneisen Stromal resistance of fibroblasts against oxidative damage: involvement of tumor cell-secreted platelet-derived growth factor (PDGF) and phosphoinositide 3-kinase (PI3K) activation Carcinogenesis, February 1, 2008; 29(2): 404 - 410. [Abstract] [Full Text] [PDF]

				H. Katayama, Y. Kusaka, H. Yokota, T. Akao, M. Kojima, O. Nakamura, E. Mekada, and E. Mizuki Parasporin-1, a Novel Cytotoxic Protein from Bacillus thuringiensis, Induces Ca2+ Influx and a Sustained Elevation of the Cytoplasmic Ca2+ Concentration in Toxin-sensitive Cells J. Biol. Chem., March 9, 2007; 282(10): 7742 - 7752. [Abstract] [Full Text] [PDF]

				S. L. Fleck, B. Birdsall, J. Babon, A. R. Dluzewski, S. R. Martin, W. D. Morgan, E. Angov, C. A. Kettleborough, J. Feeney, M. J. Blackman, et al. Suramin and Suramin Analogues Inhibit Merozoite Surface Protein-1 Secondary Processing and Erythrocyte Invasion by the Malaria Parasite Plasmodium falciparum J. Biol. Chem., November 28, 2003; 278(48): 47670 - 47677. [Abstract] [Full Text] [PDF]

				S. P. Faux, C. E. Houghton, A. Hubbard, and G. Patrick Increased expression of epidermal growth factor receptor in rat pleural mesothelial cells correlates with carcinogenicity of mineral fibres Carcinogenesis, December 1, 2000; 21(12): 2275 - 2280. [Abstract] [Full Text] [PDF]

				J. Stratmann, J. Scheer, and C. A. Ryan Suramin inhibits initiation of defense signaling by systemin, chitosan, and a beta -glucan elicitor in suspension-cultured Lycopersicon peruvianum cells PNAS, August 1, 2000; 97(16): 8862 - 8867. [Abstract] [Full Text] [PDF]

				Y.-L. Zhang, Y.-F. Keng, Y. Zhao, L. Wu, and Z.-Y. Zhang Suramin Is an Active Site-directed, Reversible, and Tight-binding Inhibitor of Protein-tyrosine Phosphatases J. Biol. Chem., May 15, 1998; 273(20): 12281 - 12287. [Abstract] [Full Text] [PDF]